Day: October 26, 2022

On November 30, 1996, Kim, Sung Hoon; Bae, Jin Seok; Hwang, Seok Hwan; Gwon, Tae Sun; Doh, Myung Ki; Park, Chul published an article.Name: 1,1′-Dipropyl-[4,4′-bipyridine]-1,1′-diium bromide The title of the article was Electrochromic properties of symmetric and asymmetric viologens. And the article contained the following:

Electrochromic properties of several viologen derivatives were examined by the cyclovoltametric and chronoamperometric methods. The electrochromic properties of 1,1′-diethyl-4,4′-bipyridinium dibromide(EV), 1,1′-dipropyl-4,4′-bipyridinium dibromide(PV), 1,1′-dibutyl-4,4′-bipyridinium dibromide(BV) and 1-butyl-1′-ethyl-4,4′-bipyridinium dibromide(EBV) were studied using an propylenecarbonate/methanol solution with Bu4NBF4 as supporting electrolyte. A monomer-dimer equilibrium might explain the observation that EV and EBV cation radical solutions shows violet under an applied voltage of 1.73̃.0 V but blue under open-circuit condition. The experimental process involved the reaction of 1,1′-Dipropyl-[4,4′-bipyridine]-1,1′-diium bromide(cas: 52243-87-5).Name: 1,1′-Dipropyl-[4,4′-bipyridine]-1,1′-diium bromide

The Article related to viologen electrochromism cyclic voltammetry chronoamperometry, diethylbipyridinium dibromide electrochromism cyclic voltammetry chronoamperometry, dipropylbipyridinium dibromide electrochromism cyclic voltammetry chronoamperometry, dibutylbipyridinium dibromide electrochromism cyclic voltammetry chronoamperometry and other aspects.Name: 1,1′-Dipropyl-[4,4′-bipyridine]-1,1′-diium bromide

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On April 2, 2021, Lu, Dengfu; Cui, Jiajia; Yang, Sen; Gong, Yuefa published an article.Category: pyridine-derivatives The title of the article was Iron-catalyzed cyanoalkylation of glycine derivatives promoted by pyridine-oxazoline ligands. And the article contained the following:

An iron-catalyzed C(sp3)-H cyanoalkylation of glycine derivatives with cyclobutanone oxime esters was established for the incorporation of a cyano group into amino acids and peptides. In this reaction, Fe(NTf2)2 and pyridine-oxazoline ligands form highly active catalysts that could simultaneously and selectively activate both substrates. Preliminary mechanistic studies revealed the excellent chemo-selectivity may stem from an in situ formed imine intermediate and a consecutive radical addition The evidence suggested the interaction between glycinate substrate and the Fe-catalyst has a prominent impact on the catalytic activity, and the catalyst may also activate the imine intermediate as a Lewis acid. The experimental process involved the reaction of 2-(4,5-Dihydro-4,4-dimethyl-2-oxazolyl)pyridine(cas: 109660-12-0).Category: pyridine-derivatives

The Article related to nitrile amino acid diastereoselective synthesis cyclic voltammetry, glycine cyanoalkylation cyclobutanone oxime ester pyridine oxazoline iron catalyst, cyanoalkylation reaction mechanism imine intermediate radical addition lewis acid, aniline substitution bromide oxime acylation cyanoalkylation mechanism lewis acid and other aspects.Category: pyridine-derivatives

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On March 13, 2003, Kajino, Masahiro; Kawada, Akira; Nakayama, Yutaka; Kimura, Haruhide published a patent.Quality Control of Ethyl 6-cyanopicolinate The title of the patent was Preparation of 2-heterocyclyl-1,3-benzothiazinone derivatives as inhibitors of apoptosis or cytoprotective agents. And the patent contained the following:

Compounds represented by the following general formula (I) or salts thereof (wherein R1 represents hydrogen, halogeno, hydroxy, nitro, optionally halogenated alkyl, optionally substituted alkoxy, acyl or optionally substituted amino; R2 represents pyridyl, furyl, thienyl, pyrrolyl, quinolyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolyl, tetrahydroquinolyl or thiazolyl, each optionally substituted; and n is 1 or 2), which and have a high safety and favorable effects of inhibiting cell death and binding to macrophage migration inhibitory factor (MIF), are prepared Also disclosed are apoptosis inhibitors, cytoprotective agents, or myocardial cell death inhibitors, or preventives/remedies for diseases caused by apoptosis or MIF which contain the compounds of the general formula (I), in particular for the prevention and/or treatment of circulatory diseases, bone or joint diseases, infectious diseases, inflammatory bowel diseases, or kidney. They are also useful for the prevention and/or treatment of heart diseases, heart failure syndromes, neurodegenerative diseases, brain vascular diseases, central nerve infections, traumatic diseases, demyelinating diseases, liver diseases, myelodysplastic syndrome, AIDS, cancer, etc. Thus, a mixture of 0.67 g thiosalicylic acid Me ester, 2-cyano-6-propylthiopyridine, and 0.84 mL Et3N in 50 mL toluene was refluxed for 48 h to give 37% 2-(6-propylthio-2-pyridyl)-4H-1,3-benzothiazin-4-one which was oxidized by m-chloroperbenzoic acid in EtOAc at room temperature for 18 h to give 2-(6-propylsulfinyl-2-pyridyl)-4H-1,3-benzothiazin-4-one (II). II was further oxidized by m-chloroperbenzoic acid in EtOAc at room temperature for 18 h to give 41% 2-(6-propylsulfonyl-2-pyridyl)-4H-1,3-benzothiazin-4-one (III). II and III showed the minium effective concentration of 0.019 and 0.010 μM, resp., for inhibiting apoptosis of new born rat’s first generation myocardial cells. A tablet and a capsule formulation containing 2-(6-methylsulfonyl-2-pyridyl)-4H-1,3-benzothiezin-4-one were described. The experimental process involved the reaction of Ethyl 6-cyanopicolinate(cas: 97483-79-9).Quality Control of Ethyl 6-cyanopicolinate

The Article related to heterocyclylbenzothiazinone preparation apoptosis inhibitor cytoprotective agent, myocardial cell death inhibitor heterocyclylbenzothiazinone preparation, circulatory disease prevention treatment heterocyclylbenzothiazinone preparation, bone joint disease prevention treatment heterocyclylbenzothiazinone preparation and other aspects.Quality Control of Ethyl 6-cyanopicolinate

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

Lv, Cong; Liu, Dan; Muschin, Tegshi; Bai, Chaolumen; Bao, Agula; Bao, Yong-Sheng published an article in 2022, the title of the article was From amides to urea derivatives or carbamates with chemospecific C-C bond cleavage at room temperature.HPLC of Formula: 156267-13-9 And the article contains the following content:

Herein, a significant advancement in this area and present a general method for copper-catalyzed chemospecific C-C bond cleavage of amides to synthesize urea derivatives and carbamates at room temperature was reported. A catalytic process via a resonant six-membered N,O-chelated copper cycle and superoxide radical was proposed according to mechanistic and control experiments The combination of chelation assistance and radical oxygenation strategies opened a door for C-C bond cleavage of common substrates which possess multiple reactive sites and was envision that this broadly applicable method will be of great interest in organic synthesis, the pharmaceutical industry and the agrochem. industry. The experimental process involved the reaction of N,3-Dimethylpyridin-2-amine(cas: 156267-13-9).HPLC of Formula: 156267-13-9

The Article related to diaryl acetamide copper catalyst chemoselective bond cleavage, aryl aldehyde preparation, amine pyridinyl diphenylacetamide copper catalyst chemoselective bond cleavage, pyridinyl urea preparation, alc methylpyridinyl diphenylacetamide copper catalyst chemoselective bond cleavage, methylpyridinyl carbamate preparation and other aspects.HPLC of Formula: 156267-13-9

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On February 11, 2016, Schwiebert, Erik; Streiff, John; Dixon, John; Gao, Hongwu; Ritchie, Joseph P.; Seales, Eric C.; Mai, Deborah published a patent.Electric Literature of 25813-24-5 The title of the patent was Coumarin derivatives and methods of use in treating hyperproliferative diseases. And the patent contained the following:

Coumarin derivative compounds and methods for the treatment of hyperproliferative diseases, such as cancer, polycystic kidney disease, and fibrosis of different tissues (e.g., idiopathic pulmonary fibrosis), are provided. The methods include administering to a subject a compound as described herein. Also provided are methods for inhibiting the interaction between two or more heat shock protein chaperones in a cell. The experimental process involved the reaction of 3,5-Dibromo-4-methoxypyridine(cas: 25813-24-5).Electric Literature of 25813-24-5

The Article related to coumarin thiazolyl derivative preparation treatment hyperproliferative disease, cancer treatment coumarin thiazolyl derivative, polycystic kidney disease treatment coumarin thiazolyl derivative, tissue fibrosis treatment coumarin thiazolyl derivative, idiopathic pulmonary fibrosis treatment coumarin thiazolyl derivative and other aspects.Electric Literature of 25813-24-5

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On September 25, 2014, Schwiebert, Erik; Streiff, John; Dixon, John; Gao, Hongwu; Ritchie, Joseph P.; Seales, Eric C.; Mai, Deborah published a patent.SDS of cas: 25813-24-5 The title of the patent was Preparation of coumarin thiazolyl derivatives and methods of use in treating hyperproliferative diseases. And the patent contained the following:

Coumarin thiazolyl derivatives I [R1 is H, halogen, OH, (un)substituted alkoxyl, (un)substituted amino, (un)substituted C1-6-alkyl, (un)substituted heterocycloalkyl; R2 is H, halogen, OH, NO2, CN, N3, thiocyanato, CF3, (un)substituted alkoxyl, (un)substituted amino, (un)substituted carbonyl, or (un)substituted C1-6-alkyl; R3 is H or substituted or unsubstituted C1-6-alkyl; R4 is (un)substituted C1-6-alkyl, (un)substituted aryl or (un)substituted heteroaryl; X is S or O; and, Y is O, NH or NMe] are provided. Thus, DBM-308 (II) was prepared from 3-chlorosalicylaldehyde via cyclocondensation with Et acetoacetate in EtOH containing piperidine to give 3-acetyl-8-chlorocoumarin (III); regioselective bromination with CuBr2 in CHCl3 to give 3-(bromoacetyl)-8-chlorocoumarin (IV); and cyclocondensation with 2-MeOC6H4NHC(:S)NH2 to give II. Methods for the treatment of hyperproliferative diseases, such as cancer, polycystic kidney disease, and fibrosis of different tissues (e.g., idiopathic pulmonary fibrosis), are provided. The antiproliferative activity of II was determined [GI50 = 166 nM; TGI = 247 nM; LC50 = >4,000 nM; IC50 = 0.69 μM vs. N828 cell line (hyperproliferative PKD cells); IC50 = 0.54 μM vs. 3-8C1 cell line (hyperproliferative PKD cells)]. The methods include administering to a subject a compound as described herein. Also provided are methods for inhibiting the interaction between two or more heat shock protein chaperones in a cell. The experimental process involved the reaction of 3,5-Dibromo-4-methoxypyridine(cas: 25813-24-5).SDS of cas: 25813-24-5

The Article related to coumarin thiazolyl derivative preparation treatment hyperproliferative disease, cancer treatment coumarin thiazolyl derivative, polycystic kidney disease treatment coumarin thiazolyl derivative, tissue fibrosis treatment coumarin thiazolyl derivative, idiopathic pulmonary fibrosis treatment coumarin thiazolyl derivative and other aspects.SDS of cas: 25813-24-5

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On September 21, 2007, Wang, Jian; Onions, Stuart; Pilkington, Melanie; Stoeckli-Evans, Helen; Halfpenny, Joan C.; Wallis, John D. published an article.Computed Properties of 75449-26-2 The title of the article was Metal catalyzed rearrangement of a 2,2′-bipyridine Schiff-base ligand to a quaterpyridine-type complex. And the article contained the following:

A Co(II) quaterpyridine-type complex, [Co(L2)(H2O)(CH3CN)](ClO4)2 (L2 = I), has been prepared via a one-pot transformation of a 2,2′-bipyridine Schiff base ligand (II) in the presence of a Lewis acidic metal salt. The mol. structure of the cobalt complex has been determined using X-ray crystallog. The experimental process involved the reaction of [2,2′-Bipyridine]-3,3′-diamine(cas: 75449-26-2).Computed Properties of 75449-26-2

The Article related to aminobipyridine pyridylpyrimidine derivative preparation structure, crystal structure aminobipyridine pyridylpyrimidine cobalt quaterpyridine derivative complex, cobalt quaterpyridine derivative complex preparation structure, pyridinecarbaldehyde aminobipyridine schiff preparation rearrangement cobalt catalyzed mechanism and other aspects.Computed Properties of 75449-26-2

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On July 16, 2015, Stoessel, Philipp; Koenen, Nils published a patent.Recommanded Product: 6-(tert-Butyl)pyridin-3-amine The title of the patent was Cyclometalated arylpyridine and arylbenzimidazolylidene metal complexes as electroluminescent materials for organic light-emitting devices. And the patent contained the following:

Cyclometalated iridium complexes [(Q1-Q2)3Ir] (1), [(Q1-Q2)2(Q3-Q4)Ir] (2) and [(Q1-Q2)2IrL] (3; for 1-3: Q1, Q3 = substituted pyridinyl-κN, quinolinyl-κN, isoquinolinyl-κN, benzimidazolylidene-κC2; Q2, Q4 = substituted aryl-κC2; L = acetylacetonato, dipivaloylmethanato), useful as triplet-emitting dopants for light-emitting layers of organic electroluminescent devices (OLEDs), featuring better solubility in organic solvents and enhanced stability, were prepared by conventional cyclometalation, ligand substitution and derivatization reactions and tested for performance and electrooptical characteristics by manufacturing test OLEDs according to standard protocols. The homoleptic complexes 1 were prepared by cyclometalation of the corresponding ligands Q1-Q2H with [Ir(acac)3], typically as fac-isomers. The heteroleptic tris-cyclometalated complexes 2 were prepared via cationic intermediates [(Q1-Q2)2Ir(HOMe)2][OTf] (4), which were results of halogen abstraction and methanolysis of iridium dimers [(Q1-Q2)4Ir2(μ-Cl)2] (5), by cyclometalation of the ligands Q3-Q4H with 4. The complexes of the type 3 were prepared by complexation of dimers 5 or methanol complexes 4 with the β-diketones HL. The ligands in the some of the complexes 1 or 2 were modified by bromination, borylation and coupling reaction sequence; the bromides [(Q1-Q2-Br)3Ir] (6) were arylated via Suzuki coupling with arylboronates or converted into aromatic amines [(Q1-Q2-NR2)3Ir] (R = aryl, or NR2 = substituted 9-carbazolyl) by Buchwald amination reaction with amines HNR2 or carbazoles. The bromides 6 were also used as comonomers in Suzuki polymerization of arene and carbazole dibromides with arylenediboronates, giving electroluminescent polyarylene-polycarbazoles containing up to 10% of [(Q1-Q2)3Ir] structural fragments. In an example, reaction of 10 mmol of Na[(acac)2IrCl2] with 40 mmol of the proligand, 2-(1,2,3,4-tetrahydro-1,4-ethano-6-naphthyl)pyridine (H-LB1) in the presence of 3-10 g of propylene glycol as solvent at reflux for 100 h gave the reaction mixture, which was diluted with 50 mL of EtOH and 50 mL of 2 N HCl, the product was filtered off, and purified by EtOAc extraction to give the invented complex [(LB1)3Ir] (1a) with 49% yield. The experimental process involved the reaction of 6-(tert-Butyl)pyridin-3-amine(cas: 39919-70-5).Recommanded Product: 6-(tert-Butyl)pyridin-3-amine

The Article related to iridium cyclometalated arylpyridine arylquinoline arylisoquinoline arylbenzimidazole complex preparation electroluminescence, electroluminescent material iridium cyclometalated complex preparation luminescence oled manufacturing, bromination borylation suzuki buchwald coupling derivatization iridium cyclometalated complex and other aspects.Recommanded Product: 6-(tert-Butyl)pyridin-3-amine

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

Davies, David L.; Fawcett, John; Garratt, Shaun A.; Russell, David R. published an article in 2004, the title of the article was Cp*Rh complexes with pyridyloxazolines: synthesis, fluxionality and applications as asymmetric catalysts for Diels-Alder reactions.Product Details of 109660-12-0 And the article contains the following content:

Half-sandwich complexes [RhCl(pymox)Cp*][SbF6] (1-7) (pymox = pyridyloxazoline) were synthesized as single diastereomers. Treatment of these with AgSbF6 generates dications [Rh(OH2)(pymox)Cp*]2+ which are fluxional at room temperature and which are enantioselective catalysts for the Diels-Alder reaction of methacrolein and cyclopentadiene. Treatment of the dication [Rh(OH2)(iPr-pymox)Cp*]2+ with [X]- gives [RhX(iPr-pymox)Cp*][SbF6] (X = Br, I) as single diastereomers while reaction with 4-Mepy (4-methylpyridine) gives [Rh(4-Mepy)(iPr-pymox)Cp*][SbF6] as a mixture of diastereomers. Two complexes, [RhCl(iPr-pymox)Cp*][SbF6] (3) and [RhCl(Bz-pymox)Cp*][SbF6] (6) were characterized by x-ray crystallog. The experimental process involved the reaction of 2-(4,5-Dihydro-4,4-dimethyl-2-oxazolyl)pyridine(cas: 109660-12-0).Product Details of 109660-12-0

The Article related to pyridyloxazoline cyclopentadienyl rhodium chloride preparation hydrolysis ligand substitution, crystal structure cyclopentadienyl pyridyloxazoline rhodium chloride, mol structure cyclopentadienyl pyridyloxazoline rhodium chloride, methacrolein diels alder reaction cyclopentadiene catalyst pyridyloxazoline rhodium chloride and other aspects.Product Details of 109660-12-0

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On December 30, 1998, Ankersen, Michael; Stidsen, Carsten Enggaard; Crider, Michael Albert published a patent.Application of 199522-66-2 The title of the patent was Preparation of thioureas as somatostatin agonists and antagonists for treating diseases related to the eye. And the patent contained the following:

The title compounds [I; m = 2-6; n = 1-3; p = 1-6; R1, R2 = H, (un)substituted C1-6 alkyl; X = S, O, NH, NCOPh, N(CN); A, B, D = (un)substituted aryl, heteroaryl], somatostatin receptor ligands of nonpeptide origin which have high and/or selective affinity to the somatostatin receptor protein designated SSTR4 (no data), and are useful for the treatment of a disease associated with an adverse condition in the retina and/or iris-ciliary body of a mammal such as high intraocular pressure (IOP) and/or deep ocular infections, were prepared and formulated. The diseases which may be treated with compounds I are e.g. glaucoma, stromal keratitis, iritis, retinitis, cataract and conjunctivitis. Compounds I are effective at 0.001-50 mg/kg/day. E.g., a 5-step synthesis of II.2HCl, starting with propane-1,3-diamine and 2-bromopyridine, is described. The experimental process involved the reaction of N1-(5-Bromopyrid-2-yl)ethane-1,2-diamine(cas: 199522-66-2).Application of 199522-66-2

The Article related to thiourea preparation formulation somatostatin agonist antagonist, glaucoma thiourea preparation formulation, eye disease thiourea preparation formulation, keratitis thiourea preparation formulation, iritis thiourea preparation formulation, retinitis thiourea preparation formulation, cataract thiourea preparation formulation and other aspects.Application of 199522-66-2

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem